Okogen Secures Ora® to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
January 5, 2017
Okogen, Inc., a developer of ophthalmic anti-infectives has secured Ora, Inc., the leading ophthalmic Contract Research Organization, to conduct the clinical studies and lead the regulatory strategy of OKG-0301 for the treatment of adenoviral conjunctivitis.
